hereditary disease

The suit comes shortly after Progenity filed for an initial public offering in which it is seeking to raise up to $122.6 million.

The Rostock, Germany-based company reported €12.1 million ($13.6 million) in revenues, missing the average analyst estimate of $14.7 million.

Blueprint provides 3,900 targeted single-gene and more than 200 panel tests covering 14 medical specialties, leveraging NGS and bioinformatics methods.

The German company reported its quarterly earnings for the first time as a public company, following the completion of its IPO on Nov. 7.

The company said three clinical centers have validated the test in a prospective clinical trial involving more than 10,000 participants.

Under the agreement, the companies plan to offer combined genetic and biochemical testing services out of Blueprint's clinical laboratory in Seattle.